Is cefixime 800 mg an appropriate regimen for treating uncomplicated gonorrhea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, cefixime 800 mg is NOT recommended as first-line treatment for gonorrhea

Cefixime is no longer recommended as a first-line regimen for gonorrhea treatment at any dose, including 800 mg, due to declining susceptibility and treatment failures, particularly for pharyngeal infections. 1

Current First-Line Recommendation

The standard of care is ceftriaxone 250 mg intramuscularly PLUS azithromycin 1 g orally as a single dose (or doxycycline 100 mg orally twice daily for 7 days). 1

Why Cefixime Is No Longer First-Line

  • Rising minimum inhibitory concentrations (MICs): From 2006-2011, there was a significant increase in N. gonorrhoeae isolates with elevated cefixime MICs, particularly in the Western United States and among men who have sex with men 1

  • Poor pharyngeal efficacy: A 400 mg oral dose of cefixime demonstrates limited efficacy for pharyngeal gonorrhea and does not provide bactericidal levels as high or sustained as ceftriaxone 250 mg IM 1

  • Treatment failures documented: Recent clinical trials show cefixime 800 mg plus doxycycline failed to achieve noninferiority to ceftriaxone plus azithromycin, with all treatment failures occurring in pharyngeal infections 2

  • Resistance concerns: The prevalence of cefixime-resistant N. gonorrhoeae has exceeded 6% in some regions, surpassing the WHO's 5% resistance threshold 3

When Cefixime 400 mg May Be Used (Not 800 mg)

Cefixime can only be considered as an alternative regimen when ceftriaxone is unavailable:

  • Dose: Cefixime 400 mg orally (not 800 mg) 1
  • Must be combined with: Azithromycin 1 g orally OR doxycycline 100 mg twice daily for 7 days 1
  • Mandatory follow-up: Test-of-cure at 1 week is required 1

FDA Labeling Context

The FDA label for cefixime indicates approval for uncomplicated gonorrhea (cervical/urethral) at 400 mg as a single oral dose 4. However, this labeling predates current CDC guidance that no longer recommends cefixime as first-line therapy due to emerging resistance patterns.

Critical Pitfalls to Avoid

  1. Do not use cefixime for pharyngeal gonorrhea: Even at 800 mg, efficacy is inadequate 2, 5

  2. Do not use cefixime monotherapy: Always combine with azithromycin or doxycycline 1

  3. Do not skip test-of-cure: If cefixime is used, culture or NAAT at 1 week is mandatory 1

  4. Do not use 800 mg dosing: While studied in research settings 2, 6, 7, the 800 mg dose is not part of current treatment guidelines and showed treatment failures

Why This Matters for Morbidity and Mortality

Using suboptimal therapy risks:

  • Treatment failure leading to ongoing transmission
  • Progression to complications: Pelvic inflammatory disease, ectopic pregnancy, infertility in women 1
  • Facilitation of HIV transmission 1
  • Accelerated development of cephalosporin resistance, potentially compromising ceftriaxone—the last highly effective single-dose treatment 1

The CDC explicitly states that continued use of cefixime might hasten resistance development to ceftriaxone, making preservation of ceftriaxone effectiveness critical for public health 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.